Akero Therapeutics Ownership | Who Owns Akero Therapeutics?


OverviewForecastFinancialsChart

Akero Therapeutics Ownership Summary


Akero Therapeutics is owned by 20.16% institutional investors, 1.38% insiders, and 78.46% retail investors. Wellington management group llp is the largest institutional shareholder, holding 10.62% of AKRO shares. Vanguard Health Care Inv is the top mutual fund, with 4.59% of its assets in Akero Therapeutics shares.

AKRO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkero Therapeutics20.16%1.38%78.46%
SectorHealthcare Stocks 278.70%10.61%-189.31%
IndustryBiotech Stocks 63.84%10.66%25.50%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wellington management group llp7.38M10.62%$205.23M
Rtw investments, lp7.42M9.43%$300.33M
Blackrock5.59M9.42%$131.06M
Janus henderson group6.03M8.69%$167.77M
Blackrock funding, inc. /de5.92M8.53%$164.81M
General atlantic5.23M7.54%$145.61M
Price t rowe associates inc /md/4.32M6.22%$120.24M
Vanguard group3.70M5.33%$103.06M
Deep track capital, lp3.21M4.08%$129.95M
State street2.34M3.36%$64.99M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Propel bio management228.88K10.76%$9.27M
University of wisconsin foundation410.63K8.30%$11.42M
Foresite capital management vi365.00K8.09%$14.78M
General atlantic5.23M5.18%$145.61M
Rtw investments, lp7.42M4.59%$300.33M
Silverarc capital management739.56K4.50%$20.57M
Deep track capital, lp3.21M4.21%$129.95M
Redmile group939.28K3.59%$38.02M
Exome asset management76.38K2.75%$3.09M
Logos global management lp800.00K2.60%$22.26M

Top Buyers

HolderShares% AssetsChange
Deep track capital, lp3.21M4.21%1.72M
Blackrock5.59M0.00%694.02K
Rtw investments, lp7.42M4.59%559.52K
Morgan stanley946.53K0.00%542.66K
Price t rowe associates inc /md/4.32M0.01%513.61K

Top Sellers

HolderShares% AssetsChange
Alkeon capital management1.76M0.10%-1.56M
Braidwell lp---1.08M
Janus henderson group6.03M0.09%-1.04M
T. rowe price investment management---670.05K
Balyasny asset management---649.13K

New Positions

HolderShares% AssetsChangeValue
Sofinnova investments510.02K1.35%510.02K$20.65M
Marshall wace, llp275.07K0.01%275.07K$7.65M
Ikarian capital245.00K1.22%245.00K$9.92M
Stempoint capital lp156.19K2.02%156.19K$6.32M
Soleus capital management117.00K0.34%117.00K$4.74M

Sold Out

HolderChange
Farther finance advisors-1.00
Newedge advisors-7.00
Nelson, van denburg & campbell wealth management group-12.00
Riggs asset managment-14.00
Continuum advisory-18.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202528-86.07%15,857,543-78.62%200.18%14-87.16%7-86.00%
Dec 31, 202419810.00%74,179,4721.61%1060.97%10727.38%50-12.28%
Sep 30, 202418014.65%72,997,3861.71%1050.72%858.97%577.55%
Jun 30, 2024157-15.14%71,768,872-1.77%1210.80%78-29.09%5312.77%
Mar 31, 20241858.82%73,065,46123.85%1231.10%11025.00%47-2.08%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv3.66M4.59%-743.67K
Vanguard Total Stock Mkt Idx Inv2.30M2.89%2.08K
Vanguard US Total Market Shares ETF1.94M2.55%2.50K
T. Rowe Price New Horizons1.81M2.38%-24.48K
US Small-Cap Growth II Equity Comp1.81M2.38%29.50K
iShares Russell 2000 ETF1.87M2.35%-
Janus Henderson Global Life Sciences1.55M1.95%-82.26K
Janus Henderson Global Life Sciences D1.55M1.94%-4.83K
T. Rowe Price Health Sciences1.24M1.63%-18.77K
Janus Global Life Science AUSD1.26M1.58%-43.35K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 07, 2025Rolph Timothy Chief Scientific OfficerSell$94.89K
Jul 07, 2025Rolph Timothy Chief Scientific OfficerSell$2.16K
Jul 07, 2025Rolph Timothy Chief Scientific OfficerSell$541.61K
Jul 01, 2025Lamy Patrick Senior VP, Commercial StrategySell$105.76K
Jun 18, 2025Cheng Andrew President and CEOSell$363.04K

Insider Transactions Trends


DateBuySell
2025 Q3-4
2025 Q2-45
2025 Q1439
2024 Q4-31
2024 Q3-26

AKRO Ownership FAQ


Who Owns Akero Therapeutics?

Akero Therapeutics shareholders are primarily institutional investors at 20.16%, followed by 1.38% insiders and 78.46% retail investors. The average institutional ownership in Akero Therapeutics's industry, Biotech Stocks , is 63.84%, which Akero Therapeutics falls below.

Who owns the most shares of Akero Therapeutics?

Akero Therapeutics’s largest shareholders are Wellington management group llp (7.38M shares, 10.62%), Rtw investments, lp (7.42M shares, 9.43%), and Blackrock (5.59M shares, 9.42%). Together, they hold 29.48% of Akero Therapeutics’s total shares outstanding.

Does Blackrock own Akero Therapeutics?

Yes, BlackRock owns 9.42% of Akero Therapeutics, totaling 5.59M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 131.06M$. In the last quarter, BlackRock increased its holdings by 694.02K shares, a 14.19% change.

Who is Akero Therapeutics’s biggest shareholder by percentage of total assets invested?

Propel bio management is Akero Therapeutics’s biggest shareholder by percentage of total assets invested, with 10.76% of its assets in 228.88K Akero Therapeutics shares, valued at 9.27M$.

Who is the top mutual fund holder of Akero Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Akero Therapeutics shares, with 4.59% of its total shares outstanding invested in 3.66M Akero Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools